{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:39:49Z","timestamp":1773196789847,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"deutsche krebshilfe","doi-asserted-by":"publisher","award":["107592"],"award-info":[{"award-number":["107592"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"deutsche krebshilfe","doi-asserted-by":"publisher","award":["110515"],"award-info":[{"award-number":["110515"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>[<jats:sup>18<\/jats:sup>F]Fluoro-deoxyglucose (FDG) positron emission tomography\/computed tomography (PET\/CT) is the standard imaging procedure in diffuse large B-cell lymphoma (DLBCL). Disease presentation, FDG-PET\/CT performance, and outcome may be influenced by germline single nucleotide polymorphisms (SNP) in genes regulating glucose uptake.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical variables, FDG-PET findings, and outcome were analysed in relation to SNPs in 342 DLBCL patients participating in the \u2018Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas\u2019 (PETAL) trial. Genes analysed included SLC2A1 (SNPs rs1385129, referred to as HaeIII; rs710218, HpyCH4V; rs841853, XbaI), VEGFA (rs3025039), HIF1A (rs11549465, P582S; rs11549467, A588T), and APEX1 (rs1130409, D148E). Statistical significance was assumed at<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.05.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The SLC2A1 HaeIII and HpyCH4V SNPs were tightly linked and statistically significantly associated with baseline maximum standardized uptake value (SUV<jats:sub>max<\/jats:sub>) and Ann Arbor stage, with slightly lower SUV<jats:sub>max<\/jats:sub>(HaeIII, median 18.9, interquartile range [IQR] 11.5\u201326.6, versus 21.6, IQR 14.4\u201329.7;<jats:italic>p<\/jats:italic>\u2009=\u20090.019) and more frequent stage IV disease (HaeIII, 44.5% versus 30.8%;<jats:italic>p<\/jats:italic>\u2009=\u20090.011) in minor allele carriers. As previously reported for lung cancer, the association was dependent upon the coexistent APEX1 D148E genotype. The HIF1A A588T SNP was associated with total metabolic tumour volume (TMTV) and time-to-progression, with significantly lower TMTV (median 16 cm<jats:sup>3<\/jats:sup>, IQR 7\u2013210, versus 146 cm<jats:sup>3<\/jats:sup>, IQR 34\u2013510;<jats:italic>p<\/jats:italic>\u2009=\u20090.034) and longer time-to-progression in minor allele carriers (log-rank<jats:italic>p<\/jats:italic>\u2009=\u20090.094). Time-to-progression was also associated with the SLC2A1 XbaI and APEX1 D148E SNPs, with shorter time-to-progression in homozygous and heterozygous SLC2A1 XbaI (HR 1.456; CI 0.930\u20132.280;<jats:italic>p<\/jats:italic>\u2009=\u20090.099) and homozygous APEX1 D148E minor allele carriers (HR 1.6; CI 1.005\u20132.545;<jats:italic>p<\/jats:italic>\u2009=\u20090.046). In multivariable analyses including SNPs, International Prognostic Index factors, sex, and B symptoms, HIF1A A588T, SLC2A1 XbaI, and APEX1 D148E retained statistical significance for time-to-progression, and SLC2A1 XbaI was also significantly associated with overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Common SNPs in genes regulating glucose uptake may impact SUV<jats:sub>max<\/jats:sub>, tumour distribution, tumour volume, and outcome in DLBCL. The effects on SUV<jats:sub>max<\/jats:sub>are of low magnitude and appear clinically negligible. The results are consistent with findings in other types of cancer. They need to be confirmed in an independent DLBCL population of sufficient size.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>Trial registration: ClinicalTrials.gov NCT00554164; EudraCT 2006-001641-33. Registration date November 5, 2007,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00554164\">https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00554164<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1007\/s00432-021-03796-z","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T17:02:41Z","timestamp":1635354161000},"page":"2611-2621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial"],"prefix":"10.1007","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4537-0964","authenticated-orcid":false,"given":"Martina","family":"Broecker-Preuss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Becher-Boveleth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan P.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2230-3873","authenticated-orcid":false,"given":"Andreas","family":"H\u00fcttmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2766-1696","authenticated-orcid":false,"given":"Christine","family":"Hanoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Grafe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-4084","authenticated-orcid":false,"given":"Julia","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-4117","authenticated-orcid":false,"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5207-3864","authenticated-orcid":false,"given":"Jan","family":"Rekowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-7862","authenticated-orcid":false,"given":"Andreas","family":"Bockisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-9472","authenticated-orcid":false,"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"3796_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood 107:265\u2013276","journal-title":"Blood"},{"key":"3796_CR2","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068","journal-title":"J Clin Oncol"},{"key":"3796_CR3","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","volume":"394","author":"V Poeschel","year":"2020","unstructured":"Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L et al (2020) Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet 394:2271\u20132281","journal-title":"Lancet"},{"key":"3796_CR4","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/JCO.20.00999","volume":"38","author":"DO Persky","year":"2020","unstructured":"Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ et al (2020) Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol 38:3003\u20133011","journal-title":"J Clin Oncol"},{"key":"3796_CR5","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1111\/febs.14577","volume":"285","author":"P-B Ancey","year":"2018","unstructured":"Ancey P-B, Contat C, Meylan W (2018) Glucose transporters in cancer\u2014from tumor cells to the tumor microenvironment. FEBS J 285:2926\u20132943","journal-title":"FEBS J"},{"key":"3796_CR6","first-page":"1","volume":"51","author":"JW Lee","year":"2019","unstructured":"Lee JW, Ko J, Ju C, Eltzschig HK (2019) Hypoxia signaling in human diseases and therapeutic targets. Exp Mol Med 51:1\u201313","journal-title":"Exp Mol Med"},{"key":"3796_CR7","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N (2019) VEGF in signaling and disease: beyond discovery and development. Cell 176:1248\u20131264","journal-title":"Cell"},{"key":"3796_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41698-017-0023-0","volume":"1","author":"F Shah","year":"2017","unstructured":"Shah F, Logsdon D, Richard A, Messmann RA, Fehrenbacher JC, Fishel ML, Kelley MR (2017) Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. NPJ Precis Oncol 1:19","journal-title":"NPJ Precis Oncol"},{"key":"3796_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3109\/09687688.2011.554447","volume":"28","author":"T Amann","year":"2011","unstructured":"Amann T, Kirovski G, Bosserhoff AK, Hellerbrand C (2011) Analysis of a promoter polymorphism of the GLUT1 gene in patients with hepatocellular carcinoma. Mol Membr Biol 28:182\u2013186","journal-title":"Mol Membr Biol"},{"key":"3796_CR10","doi-asserted-by":"publisher","first-page":"56850","DOI":"10.18632\/oncotarget.18090","volume":"8","author":"W Feng","year":"2017","unstructured":"Feng W, Cui G, Tang C-W, Zhang X-L, Dai C, Xu Y-Q et al (2017) Role of glucose metabolism related gene GLUT1 in the occurrence and prognosis of colorectal cancer. Oncotarget 8:56850\u201356857","journal-title":"Oncotarget"},{"key":"3796_CR11","doi-asserted-by":"crossref","unstructured":"Heist RS, Zhai R, Liu G, Zhou W, Lin X, Su Li, et al (2008) VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 26:856\u201362.","DOI":"10.1200\/JCO.2007.13.5947"},{"key":"3796_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1349-7006.2011.02168.x","volume":"103","author":"MK Kim","year":"2012","unstructured":"Kim MK, Suh C, Chi HS, Cho HS, Bae YK, Lee KH et al (2012) VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma. Cancer Sci 103:497\u2013503","journal-title":"Cancer Sci"},{"key":"3796_CR13","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/carcin\/bgg132","volume":"24","author":"K Tanimoto","year":"2003","unstructured":"Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T et al (2003) Hypoxia-inducible factor-1\u03b1 polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24:1779\u20131783","journal-title":"Carcinogenesis"},{"key":"3796_CR14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/mc.20655","volume":"49","author":"G Knechtel","year":"2010","unstructured":"Knechtel G, Szkandera J, Stotz M, Hofmann G, Langsenlehner U, Krippl P et al (2010) Single nucleotide polymorphisms in the hypoxia-inducible factor-1 gene and colorectal cancer risk. Mol Carcinog 49:805\u2013809","journal-title":"Mol Carcinog"},{"key":"3796_CR15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/annonc\/mdr325","volume":"23","author":"C Qin","year":"2012","unstructured":"Qin C, Cao Q, Ju X, Wang M, Meng X, Zhu J et al (2012) The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma. Ann Oncol 23:981\u2013989","journal-title":"Ann Oncol"},{"key":"3796_CR16","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1182\/blood-2005-01-026690","volume":"108","author":"DA Hill","year":"2006","unstructured":"Hill DA, Wang SS, Cerhan JR, Davis S, Cozen W, Severson RK et al (2006) Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood 108:3161\u20133167","journal-title":"Blood"},{"key":"3796_CR17","doi-asserted-by":"crossref","unstructured":"Matakidou A, El Galta R, Webb EL, Rudd MF, Bridle H, GELCAPS Consortium et al (2007) Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet 16:2333\u201340","DOI":"10.1093\/hmg\/ddm190"},{"key":"3796_CR18","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1093\/carcin\/bgn193","volume":"29","author":"TR Smith","year":"2008","unstructured":"Smith TR, Levine EA, Freimanis RI, Akman SA, Allen GO, Hoang KN et al (2008) Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. Carcinogenesis 29:2132\u20132138","journal-title":"Carcinogenesis"},{"key":"3796_CR19","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/mc.20791","volume":"50","author":"Q Cao","year":"2011","unstructured":"Cao Q, Qin C, Meng X, Ju X, Ding Q, Wang M et al (2011) Genetic polymorphisms in APE1 are associated with renal cell carcinoma risk in a Chinese population. Mol Carcinog 50:863\u2013870","journal-title":"Mol Carcinog"},{"key":"3796_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10549-004-0724-2","volume":"88","author":"G Wolf","year":"2004","unstructured":"Wolf G, Aigner RM, Schaffler G, Langsenlehner U, Renner W, Samonigg H et al (2004) The 936C>T polymorphism of the gene for vascular endothelial growth factor is associated with 18F-fluorodeoxyglucose uptake. Breast Cancer Res Treat 88:205\u2013208","journal-title":"Breast Cancer Res Treat"},{"key":"3796_CR21","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2967\/jnumed.110.075721","volume":"51","author":"F Grabellus","year":"2010","unstructured":"Grabellus F, Sheu S-Y, Bachmann HS, Lehmann N, Otterbach F, Heusner TA et al (2010) The XbaI G>T polymorphism of the glucose transporter 1 gene modulates 18F-FDG uptake and tumor aggressiveness in breast cancer. J Nucl Med 51:1191\u20131197","journal-title":"J Nucl Med"},{"key":"3796_CR22","doi-asserted-by":"crossref","unstructured":"Kim S-J, Hwang S-H, Kim IJ, Lee MK, Lee CH, Lee S-Y, Lee EY (2010) The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients. J Exp Clin Cancer Res 29:69","DOI":"10.1186\/1756-9966-29-69"},{"key":"3796_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1756-9966-32-23","volume":"32","author":"V Bravat\u00e0","year":"2013","unstructured":"Bravat\u00e0 V, Stefano A, Cammarata FP, Minafra L, Russo G, Nicolosi S et al (2013) Genotyping analysis and 18FDG uptake in breast cancer patients: a preliminary research. J Exp Clin Cancer Res 32:23","journal-title":"J Exp Clin Cancer Res"},{"key":"3796_CR24","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","volume":"36","author":"U D\u00fchrsen","year":"2018","unstructured":"D\u00fchrsen U, M\u00fcller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R et al (2018) Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A multicenter, randomized phase III trial. J Clin Oncol 36:2024\u20132034","journal-title":"J Clin Oncol"},{"key":"3796_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41408-019-0230-8","volume":"9","author":"J Richter","year":"2019","unstructured":"Richter J, H\u00fcttmann A, Rekowski J, Schmitz C, G\u00e4rtner S, Rosenwald A et al (2019) Molecular characteristics of diffuse large B-cell lymphoma in Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: Correlation with interim PET and outcome. Blood Cancer J 9:67","journal-title":"Blood Cancer J"},{"key":"3796_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2967\/jnumed.120.244145","volume":"62","author":"J Rekowski","year":"2021","unstructured":"Rekowski J, H\u00fcttmann A, Schmitz C, M\u00fcller SP, Kurch L, Kotzerke J et al (2021) Interim PET evaluation in diffuse large B-cell lymphoma employing published recommendations: comparison of the Deauville 5-point scale and the \u0394SUVmax method. J Nucl Med 62:37\u201342","journal-title":"J Nucl Med"},{"key":"3796_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejca.2019.09.027","volume":"124","author":"C Schmitz","year":"2020","unstructured":"Schmitz C, H\u00fcttmann A, M\u00fcller SP, Hanoun M, Boellaard R, Brinkmann M et al (2020) Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. Eur J Cancer 124:25\u201336","journal-title":"Eur J Cancer"},{"key":"3796_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275\u2013282","journal-title":"Blood"},{"key":"3796_CR29","doi-asserted-by":"publisher","first-page":"R6","DOI":"10.1186\/bcr3087","volume":"14","author":"LP Schwab","year":"2012","unstructured":"Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smith KD et al (2012) Hypoxia-inducible factor 1\u03b1 promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res 14:R6","journal-title":"Breast Cancer Res"},{"key":"3796_CR30","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1200\/JCO.2009.24.1893","volume":"28","author":"AM Evens","year":"2010","unstructured":"Evens AM, Sehn LH, Farinha P, Nelson BP, Raji A, Lu Y et al (2010) Hypoxia-inducible factor-1\u03b1 expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 28:1017\u20131024","journal-title":"J Clin Oncol"},{"key":"3796_CR31","doi-asserted-by":"publisher","first-page":"26293","DOI":"10.18632\/oncotarget.8477","volume":"7","author":"L Lirussi","year":"2016","unstructured":"Lirussi L, Antoniali G, D\u2019Ambrosio C, Scaloni A, Nilsen H, Tell G (2016) APE1 polymorphic variants cause persistent genomic stress and affect cancer cell proliferation. Oncotarget 7:26293\u201326306","journal-title":"Oncotarget"},{"key":"3796_CR32","doi-asserted-by":"publisher","first-page":"608","DOI":"10.2967\/jnumed.118.209544","volume":"60","author":"BF Kurland","year":"2019","unstructured":"Kurland BF, Peterson LM, Shields AT, Lee JH, Byrd DW, Novakova-Jiresova A et al (2019) Test-retest reproducibility of 18 F-FDG PET\/CT uptake in cancer patients within a qualified and calibrated local network. J Nucl Med 60:608\u2013614","journal-title":"J Nucl Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03796-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03796-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03796-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T22:15:23Z","timestamp":1726006523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03796-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3796"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03796-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"29 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"UD: Institutional research grants and honoraria from Amgen Germany and Roche Pharma. The other authors report no potential conflicts of interest relevant to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University of Duisburg-Essen (No. 07-3366). All patients gave written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}